Age: 14.0
Sex: M
Vaccine: HEP, HEP, HEPAB
Symptoms: Inappropriate schedule of product administration, Incomplete course of vaccination, Product administered to patient of inappropriate age
Clinical narrative: Patient received a shot of Havrix on Sep 7th, 2023 and two doses of Engerix-B; Inapprpriate age at vaccination; First shot was administered on on Sep 7th, 2023 and the Second shot was administered on October 27th, 2023; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 15-year-old male patient who received HAB (Twinrix) (batch number 797F9, expiry date 30-DEC-2025) for prophylaxis.   Co-suspect products included HBV (Engerix B) for prophylaxis and HBV (Engerix B) for prophylaxis.   Previously administered products included Havrix (Received a shot of Havrix on 7th September 2023) and Engerix B (Received 1st dose of Engerix B on 7th September 2023).   On 15-APR-2024, the patient received the 1st dose of Twinrix. On 27-OCT-2023, the patient received the 2nd dose of Engerix B. On an unknown date, the patient did not receive the 3rd dose of Engerix B. On 27-OCT-2023, not applicable after receiving Twinrix and Engerix B and an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: First shot was administered on on Sep 7th, 2023 and the Second shot was administered on October 27th, 2023). On 15-APR-2024, the patient experienced inappropriate age at vaccine administration (Verbatim: Inapprpriate age at vaccination). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: Patient received a shot of Havrix on Sep 7th, 2023 and two doses of Engerix-B). The outcome of the inappropriate age at vaccine administration, drug dose administration interval too long and incomplete course of vaccination were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 07-MAY-2024 The nurse called reported that, they had a patient (kid), a 15 years old patient got immunized with one of GlaxoSmithKline's product as the Centers for Disease Control and Prevention recommendation, they were vaccinated with Twinrix and the Centers for Disease Control and Prevention recommends this to be used for adults. The nurse we just wanted to see how do you approach with mixed dose and what was really the next vaccination. The nurse asked what was the next step in giving, do they give hepatitis A on its own, hepatitis B just depending on what they're already had on here. The patient did previously get doses of hepatitis A and hepatitis B separately. The patient was not immunocompromised.  The patient received a shot of Havrix on September 7th, 2023 and two doses of Engerix B. The 1st shot was administered on on September 7th, 2023 and the 2nd shot was administered on October 27th, 2023 which led to drug dose administration interval too long. Till the time of reporting the patient did not received the 3rd dose of Engerix B which led to incomplete course of vaccination. The reporter consented to follow up.